Trip.com Group Unveils Sustainability Report, Highlights Green Travel, Inclusivity
In its commitment to sustainable travel, Trip.com Group launched a new feature that provides quantified carbon emissions data for all major transportation services. In 2024 alone, the Group encouraged over 100 million orders on more sustainable travel products. Furthermore, solar panel installations at its headquarters and rural retreats generated 457 MWh of clean electricity, offsetting 245+ tons of CO2 emissions. The company also increased its use of green electricity in leased data centers to 42.6%.
A customer in a travel agents office, highlighting the convenience of the companies corporate travel solutions.
The Group's Country Retreat Programme continued to contribute to rural development, expanding to 34 sites and generating 40,000+ indirect job opportunities. Over 80% of employees at these retreats are local residents. Notably, as of July this year, women constitute 57.1% of Trip.com Group's global workforce.
Trip.com Group Limited (NASDAQ:TCOM) is a travel service provider for accommodation reservation, transportation ticketing, packaged tours, and other travel-related services in China and internationally.
While we acknowledge the potential of TCOM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the .
READ NEXT: and .
Disclosure: None. This article is originally published at Insider Monkey.
Error in retrieving data
Sign in to access your portfolio
Error in retrieving data
Error in retrieving data
Error in retrieving data
Error in retrieving data
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
These 2 Momentum Stocks Got a Bullish Nod — Here's Why They Could Reach New Highs
Buying into rising stocks is a natural impulse – and it's a viable investing strategy. Momentum investing, as it's called, is the art of finding and following the market's upward trends. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Of course, every investing style has its boosters and its bummers, and both sides usually have strong arguments in their favor. The key to success is finding balance, and remembering that while past performance won't guarantee a future return, it can still provide useful indications of where a stock is heading. With that in mind, let's dive into a pair of momentum stocks that are currently catching investors' attention. Using the TipRanks database, we've zeroed in on two names that have not only gained steam lately, but have also received bullish endorsements from at least one Street analyst. Let's take a look. BridgeBio Pharma (BBIO) The first momentum stock on our list today is BridgeBio, a biopharmaceutical company with a focus on genetic diseases that are both rare and serious. More specifically, BridgeBio has chosen disease targets with what it describes as 'clear genetic drivers'; that is, it is developing drug candidates to treat diseases that are genetically linked to single mutations. BridgeBio has chosen a rich field in which to work, as it can choose from more than 10,000 genetic diseases that meet its target criteria – and they impact tens of millions of patients globally. More importantly, this group of diseases has relatively few FDA-approved medications, giving BridgeBio plenty of openings. BridgeBio bases its development work on its proprietary drug development platform, looking for novel genetic diseases to target and then creating new medicines to address symptoms and improve patient outcomes. The company follows this development stage by moving a drug candidate from a successful clinical trial series and into the regulatory process, with commercialization being the final goal. BridgeBio reached that goal late last year. This past November, the company received FDA approval of its drug acoramidis for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM), a disease that affects the heart muscle. Treatment with acoramidis was shown in clinical trials to reduce death and hospitalization from the disease, with statistically significant improvements in patients under treatment. BridgeBio is marketing the new drug under the brand name Attruby, and 1Q25 was the company's first full quarter of commercialization efforts. The company is still investigating acoramidis in the clinical trial program, where it is the subject of the Phase 3 ACT-EARLY study, testing whether the drug is useful in preventing asymptomatic patients who carry the pathogenic TTR variant from developing the active disease. Turning to the company's financial side, we find that BridgeBio's 1Q25 earnings release showed $116.6 million in total revenues, of which $36.7 million was net product revenue derived from sales of Attruby in the US following the drug's commercial launch. The balance of the company's revenue came from license and services income. Compared to the prior-year quarter, this segment of the revenue was down by $131.2 million, leading to the total revenue year-over-year decline of 45%, although the total haul actually beat Street expectations by $58 million, aided by Atturby's better-than-expected debut. BridgeBio ran a net loss in 1Q25, of 88 cents per share, yet this was 5 cents per share better than had been expected. Investors have liked the story here and the stock shows a strong gain for the year-to-date, up ~74%. BridgeBio has caught the attention of Oppenheimer analyst Trevor Allred, who is taking a more bullish stance on the shares in light of Attruby's successful commercialization. Allred writes, 'We've been wrong on BBIO since our initiation—Bridgebio's team has executed Attruby's launch superbly, and shares have been supported by commercial outperformance and a look-ahead to clinical catalysts at YE. Our trepidation around 2029 generic entry has not mattered for 2025 stock performance. We expect share outperformance to continue as 2025 Attruby sales clear consensus estimates, and we expect commercial success to be compounded by positive clinical results from ADH1 and LGMD2i clinical trials around YE. Our concerns regarding long-term revenue durability remain, but BBIO has time to demonstrate real-world datasets demonstrating benefit over tafamidis should generics become available in 2029.' Allred follows these comments with an upgrade from Perform (i.e., Neutral) to Outperform (i.e., Buy) rating for BBIO, and a $60 price target that implies a one-year upside potential of 26%. (To watch Allred's track record, click here) Overall, this stock has earned a Strong Buy consensus rating from the Street, based on 18 recent reviews that have a lopsided breakdown of 17 Buys to 1 Hold. The shares are priced at $47.69, and their $62.75 average target price suggests that the stock will gain 31.5% by this time next year. (See BBIO stock forecast) So-Young International (SY) Next up on our list of momentum stocks is So-Young, a Chinese company. The firm that operates a social media platform, linked to the medical aesthetics industry, and connecting the varied consumers, professionals, and medical service providers in the aesthetics sector. The platform makes available reliable and trustworthy information on a carefully vetted and curated network of medical aesthetic providers. The service platform focuses on content distribution in China, making use of major social media networks and other targeted media platforms. Social media and medical aesthetics are both growth industries, and So-Young is building a brand image based on user trust, an extensive reach, and valuable data insights. So-Young's user base can trade information on clinics, the latest treatment trends in aesthetics, and the quality of treatment, all permitting better patient decisions – and based on the trust engendered by sharing personal experiences. The company is working to expand its network, to add additional medical fields such as dentistry, dermatology, ophthalmology, and basic physical exams. The service is focused on China, and the company is based in Beijing. In its financial release for 1Q25, So-Young reported important gains in the number of active users on its network and the number of verified paid visits. The active users – defined as those who had visited an aesthetic clinic at least once in the previous 12 months – totaled more than 75,500, a massive gain from the 8,000 reported in the prior-year period. The gain in verified paid visits was similar, with 45,500 in 1Q25 compared to 4,600 in 1Q24. The company reported Q1 revenue at the high end of its previously published guidance range, with a top line of RMB297.3 million (approximately US$41 million) compared with RMB318.3 million in the first quarter of 2024, a figure that beat Street expectations by $0.8 million. The shares have been on a huge runup, up 411% this year, the bulk of the gains generated over the past month and this Chinese momentum stock has come to the attention of Citi analyst Nelson Cheung, who is impressed by the company's recent growth. Cheung says of So-Young and its prospects, 'Since launch in Nov 2024, SoYoung Clinic has quickly expanded with 31 centers in major cities (Beijing, Shanghai, Shenzhen) by end-Jun, verifying SY's strength in 1) differentiating brand position for quality standardized service and value-for-money mindshare for mass public; 2) increasing pricing power over procurement as it scales up; 3) effective online private domain cross-selling for accurate targeting and site selection; 4) proven execution for profitable store management with ~80% aesthetic centers generating +ve op cash flow in 1Q. We see meaningful catalysts to drive stock price further if: 1) improving monthly sales for flagship stores in Jun (e.g. Beijing Baoli); 2) potential exploration of full managed franchising model by end 2025; 3) solid exclusive product pipeline until 2027E.' (To watch Cheung's track record, click here) Looking forward, Cheung rates this stock as a Buy, with a $5.50 price target that suggests a one-year gain for the stock of 30%. Cheung's is the only analyst review on file for this stock, which is currently trading for $4.24. (See SY stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31 minutes ago
- Yahoo
Nvidia's Huang says 'doing our best' to serve Chinese market
Nvidia CEO Jensen Huang said on Wednesday his firm was "doing our best" to serve China's vast market for semiconductors after it secured permission from the United States to sell chips to the world's second-largest economy. Nvidia last week became the first company to hit $4 trillion in market value -- a new milestone in Wall Street's bet that artificial intelligence will transform the global economy. The firm now has a market value greater than the GDP of France, Britain or India, a testament to investor confidence that AI will spur a new era of robotics and automation. But it has also found itself in the crosshairs of a brutal China-US battle for dominance in semiconductor production, vital to the manufacturing of smartphones, wind turbines, military equipment and other goods. In a rare concession, Nvidia said on Tuesday it will resume sales of its H20 AI chips to China after Washington pledged to remove licensing restrictions that had halted exports. Huang is in the Chinese capital this week to attend the China International Supply Chain Expo, a forum for the country to boost its image as the global defender of free trade in contrast to the tariff chaos sparked by US President Donald Trump. - China 'open and stable' - He told reporters at that expo that top officials, including Vice Premier He Lifeng, had assured him this week that China was "open and stable". They discussed "China welcoming foreign companies to invest here and build businesses here and that China is open and stable", he said. Huang also said he assured them his firm was keen to serve the massive Chinese market for microchips needed in everything from mobile phones to electric vehicles. "They want to know that Nvidia continues to invest here, that we are still doing our best to serve the market here," he said. Huang also addressed the expo's opening ceremony on Wednesday morning, when he hailed China's role in pioneering AI. "China's open-source AI is a catalyst for global progress, giving every country and industry a chance to join the AI revolution," he said in reference to Chinese AI startup DeepSeek. Huang also praised China's "super-fast" innovation, powered by its "researchers, developers and entrepreneurs". - Opening up - The California-based company produces some of the world's most advanced semiconductors but cannot ship its most cutting-edge chips to China due to concerns that Beijing could use them to enhance military capabilities. Nvidia developed the H20 -- a less powerful version of its AI processing units -- specifically for export to China. That plan stalled when the Trump administration tightened export licensing requirements in April. But Nvidia said this week Washington had told it that "licences will be granted, and Nvidia hopes to start deliveries soon". The announcement from Nvidia boosted tech firms around the world, with Wall Street's Nasdaq exchange rising to another record high. Asked on Wednesday about whether he had sought to sway Trump on export controls before heading to China, Huang said: "I don't think I changed his mind." "It's my job to inform the president about what I know very well, which is the technology industry, artificial intelligence," he told reporters. "This is a once-in-a-lifetime opportunity for America to have AI technology leadership," he said. Huang stressed that any discussion was between the Chinese and US governments and has "nothing to do with me". The tightened US export curbs come as China's economy wavers, with domestic consumers reluctant to spend and a prolonged property sector crisis weighing on growth. President Xi Jinping has called for greater self-reliance in the face of increasing external uncertainty. sam-pfc-oho/pbt/dhw Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31 minutes ago
- Yahoo
PCAOB chair Erica Williams to step down
The Public Company Accounting Oversight Board's (PCAOB) chair Erica Williams has decided to step down from her position. Williams was sworn in as chair in January 2022 and reappointed in October 2024. Williams said: 'With high economic uncertainty increasing the risk of fraud, the PCAOB's mission is as important as ever. It's critical that the expert PCAOB staff continue to be empowered to carry out their work of ensuring American investors are protected.' During her tenure, Williams executed a strategic plan focused on the modernisation of auditing standards, the enhancement of inspection processes, enforcement mechanisms, and the board's operational effectiveness, the PCAOB said in its press statement. Under her leadership, the PCAOB has completed access for the first time to inspect and investigate China-headquartered businesses, resulting in enforcement actions against these entities. Williams' term has been marked by various formal actions, with seven projects covering 24 rules and standards finalised during her tenure. The authority delivered sanctions, with the message that violations that put investors at risk will be met with serious consequences. Williams also oversaw the reconstitution of the Investor Advisory Group and the Standards and Emerging Issues Advisory Group. She also established the PCAOB's first-ever Office of the Investor Advocate. However, Williams' resignation comes amidst media reports suggesting that her departure was requested by Securities and Exchange Commission chairman Paul Atkins. An email sent by Williams to PCAOB staff indicated that she had been asked to resign with Atkins accepting her resignation. The email stated: 'Today, I accepted Erica Williams' offer to resign as chair and a board member of the PCAOB and thanked her for her service. I am grateful she has agreed to stay on until July 22.' Last month, the PCAOB imposed fines totalling $8.5m on the Netherlands member businesses of Deloitte, PwC, and EY for cheating in internal exams. "PCAOB chair Erica Williams to step down " was originally created and published by The Accountant, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
